Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults.

There is little scientific evidence that supports the use of initial systemic dosing that exceeds 0.8 mg in the community. Higher doses increase the risk of withdrawal symptoms feared in people who use opioids. Many obstacles may reduce the potential of community-administered naloxone.